Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tofacitinib Citrate

FDA-approved product (tablet, oral), marketed as Tofacitinib Citrate, Xeljanz, Xeljanz Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tofacitinib Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriatic arthritis
  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tofacitinib Citrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tofacitinib Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study

    NCT03772145 · start 2018-11-27

    Registered record
    Registry ID
    NCT03772145
    Conditions
    Ulcerative Colitis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2018-11-27
    Completion
    2024-01-29
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

    NCT03103412 · start 2017-05-04

    Registered record
    Registry ID
    NCT03103412
    Conditions
    Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
    Interventions
    TD-3504; 15N2-tofacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-04
    Completion
    2017-11-08
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
    InterventionTD-3504; 15N2-tofacitinib; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

    NCT03159936 · start 2017-04-03

    Registered record
    Registry ID
    NCT03159936
    Conditions
    Discoid Lupus Erythematosus; Systemic Lupus Erythematosus
    Interventions
    Tofacitinib citrate
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2017-04-03
    Completion
    2020-06-10
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiscoid Lupus Erythematosus; Systemic Lupus Erythematosus
    InterventionTofacitinib citrate
    PhaseEarly phase 1
    Registry statusTerminated

  • Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

    NCT02299297 · start 2015-01

    Registered record
    Registry ID
    NCT02299297
    Conditions
    Alopecia Areata
    Interventions
    Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01
    Completion
    2017-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia Areata
    InterventionTofacitinib
    PhasePhase 2
    Registry statusCompleted

  • A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

    NCT02193815 · start 2014-09

    Registered record
    Registry ID
    NCT02193815
    Conditions
    Psoriasis Vulgaris
    Interventions
    PF06263276; Vehicle; 2%Tofacitinib Ointment; Vehicle; Daivonex; Daivonex Ointment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09
    Completion
    2015-02
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis Vulgaris
    InterventionPF06263276; Vehicle; 2%Tofacitinib Ointment; Vehicle +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

    NCT02147587 · start 2014-06

    Registered record
    Registry ID
    NCT02147587
    Conditions
    Rheumatoid Arthritis
    Interventions
    Tofacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-06
    Completion
    2015-07
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionTofacitinib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

    NCT02001181 · start 2013-12

    Registered record
    Registry ID
    NCT02001181
    Conditions
    Dermatitis, Atopic
    Interventions
    Tofacitinib ointment 20mg/g; Placebo ointment (Vehicle)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-09
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionTofacitinib ointment 20mg/g; Placebo ointment (Vehicle)
    PhasePhase 2
    Registry statusCompleted

  • A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

    NCT01731327 · start 2012-11

    Registered record
    Registry ID
    NCT01731327
    Conditions
    Healthy
    Interventions
    tofacitinib modified-release (MR) formulation; tofacitinib modified-release (MR) formulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-11
    Completion
    2012-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiontofacitinib modified-release (MR) formulation; tofacitinib modified-release (MR) formulation
    PhasePhase 1
    Registry statusCompleted

  • A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

    NCT01393626 · start 2011-10

    Registered record
    Registry ID
    NCT01393626
    Conditions
    Crohn's Disease
    Interventions
    Placebo; CP-690,550; CP-690,550
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-10
    Completion
    2015-03
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionPlacebo; CP-690,550; CP-690,550
    PhasePhase 2
    Registry statusCompleted

  • Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

    NCT01262118 · start 2011-05

    Registered record
    Registry ID
    NCT01262118
    Conditions
    Rheumatoid Arthritis
    Interventions
    CP-690,550 (tasocitinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-05
    Completion
    2012-02
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionCP-690,550 (tasocitinib)
    PhasePhase 1
    Registry statusCompleted

  • A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

    NCT01241591 · start 2010-11

    Registered record
    Registry ID
    NCT01241591
    Conditions
    Psoriasis
    Interventions
    CP 690,550 5 mg; CP 690,550 10 mg; Etanercept 50 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-11
    Completion
    2013-01
    Enrolment
    1,101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionCP 690,550 5 mg; CP 690,550 10 mg; Etanercept 50 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

    NCT01204112 · start 2010-09

    Registered record
    Registry ID
    NCT01204112
    Conditions
    Healthy
    Interventions
    Tasocitinib (CP-690,550) plus Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-09
    Completion
    2010-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTasocitinib (CP-690,550) plus Rifampin
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers

    NCT01185184 · start 2010-08

    Registered record
    Registry ID
    NCT01185184
    Conditions
    Healthy
    Interventions
    CP-690,550
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-08
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCP-690,550
    PhasePhase 1
    Registry statusCompleted

  • Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

    NCT00960440 · start 2009-10

    Registered record
    Registry ID
    NCT00960440
    Conditions
    Arthritis, Rheumatoid
    Interventions
    CP-690,550; CP-690,550; Placebo; CP-690,550; Placebo; CP-690,550
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10
    Completion
    2011-03
    Enrolment
    399

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis, Rheumatoid
    InterventionCP-690,550; CP-690,550; Placebo; CP-690,550 +2 more
    PhasePhase 3
    Registry statusCompleted

  • A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers

    NCT00860496 · start 2009-06

    Registered record
    Registry ID
    NCT00860496
    Conditions
    Healthy Volunteers
    Interventions
    CP- 690,550 and Tacrolimus; CP- 690,550 and Cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2009-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionCP- 690,550 and Tacrolimus; CP- 690,550 and Cyclosporine
    PhasePhase 1
    Registry statusCompleted